Paratek Pharmaceuticals (NASDAQ:PRTK) received a $50.00 price target from equities researchers at Cantor Fitzgerald in a report released on Wednesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 170.27% from the company’s previous close.
PRTK has been the topic of several other reports. BidaskClub downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 18th. Robert W. Baird restated a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Guggenheim began coverage on Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $40.00.
Paratek Pharmaceuticals (NASDAQ PRTK) traded down $0.35 during mid-day trading on Wednesday, reaching $18.50. The company had a trading volume of 138,474 shares, compared to its average volume of 362,900. Paratek Pharmaceuticals has a one year low of $13.95 and a one year high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. The company has a market cap of $526.69, a price-to-earnings ratio of -4.96 and a beta of 0.70.
WARNING: “Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/05/paratek-pharmaceuticals-prtk-pt-set-at-50-00-by-cantor-fitzgerald.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.